Latest News and Press Releases

UTRECHT, The Netherlands and PHILADELPHIA and FRAMINGHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that...

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that the U.S. Food and...

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by LAVA Therapeutics N.V. (Nasdaq: LVTX), please note that in...

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing bispecific gamma...

Enrollment continues in Phase 1/2a trial evaluating LAVA-051 in hematological malignancies CTA accepted and IND cleared for Phase 1/2a trial evaluating LAVA-1207 in metastatic castrate resistant...

评估LAVA-051针对血液恶性肿瘤效果的1/2a期试验的患者招募工作正在继续 评估LAVA-1207针对转移性去势抵抗性前列腺癌效果的1/2a期试验的CTA已被接受，IND得到许可；有望在今年晚些时候开始 与Janssen Biotech, Inc.的合作一直在顺利进行，并正在朝着预计的里程碑迈进 预计将为2023年下半年的业务提供1.51亿美元现金余额 荷兰乌得勒支和费城, Aug. ...

荷兰乌得勒支和费城, July 28, 2021 (GLOBE NEWSWIRE) -- 专注于开发双特异性γ-δ T细胞衔接抗体以改变癌症治疗的临床阶段生物技术公司LAVA Therapeutics N.V.（Nasdaq: LVTX）今天宣布，任命Amy Garabedian为总法律顾问兼公司秘书。Garabedian女士是位经验丰富的领导者，在生命科学行业拥有广泛的企业和事务专业知识。 ...